All News

13 March 2008

Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic CancerAntibodies

12 March 2008

BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodiesAntibodies

12 March 2008

Amgen Statement on Successful Outcome of Romiplostim Panel MeetingAntibodies

11 March 2008

Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer TrialsAntibodies

10 March 2008

iCo Therapeutics Provides iCo-008 Phase II Clinical UpdateAntibodies

5 March 2008

Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal AntibodyAntibodies

5 March 2008

Phase I/II Studies of IMC-A12 in Pediatric Cancer Patients Commence EnrollmentAntibodies

4 March 2008

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)Antibodies

4 March 2008

UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn’s Disease PatientsAntibodies

3 March 2008

Genmab and Pepscan to Identify Human Antibodies Against Intractable TargetsAntibodies

3 March 2008

BioWa Announces Expansion of License Agreement With Genetech for BioWa’s POTELLIGENT(R) TechnologyAntibodies

29 February 2008

Herceptin approved in Japan for early treatment in patients with HER2-positive breast cancerAntibodies

27 February 2008

FDA Approves Regeneron’s ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)Antibodies

27 February 2008

MorphoSys and Sigma-Aldrich Enter into a Collaboration and Licensing Agreement for Recombinant Research AntibodiesAntibodies

26 February 2008

Bradmer announces phase ii results published in newly diagnosed Glioblastoma which demonstrate improved survival and support upcoming Phase III studyAntibodies

25 February 2008

ESBATech’s Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery Via Eye DropsAntibodies

22 February 2008

Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin TrialAntibodies

22 February 2008

Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic ArthritisAntibodies

22 February 2008

Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient EnrollmentAntibodies

22 February 2008

FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast CancerAntibodies

21 February 2008

MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody TherapiesAntibodies

21 February 2008

Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanomaAntibodies

20 February 2008

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone LossAntibodies

19 February 2008

InNexus Biotechnology Announces Second Preclinical Candidate DXL702 (HER2/neu) Targeting Breast CancerAntibodies

19 February 2008

Biolex Therapeutics Enters Into Agreement With Merck KGaA for Antibody OptimizationAntibodies

18 February 2008

Takeda Discontinues Development of MatuzumabAntibodies

18 February 2008

EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus RoyaltiesAntibodies

13 February 2008

Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpointAntibodies

13 February 2008

Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of AdenocarcinomasAntibodies

13 February 2008

YM BioSciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain CaincerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Nectin-4-Targeted Immunotherapy Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review